Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

1.150 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,071,109
Open	1.180
Bid (Size)	1.150 (9,400)
Ask (Size)	1.180 (100)
Prev. Close	1.150
Today's Range	1.130 - 1.205
52wk Range	0.8332 - 5.550
Shares Outstanding	38,245,287
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Unusual volume stocks in Tuesday's session ↗

December 23, 2025

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Top movers in Thursday's session ↗

December 18, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Performance

YTD	N/A	N/A
1 Month	-70.6%	-70.6%
3 Month	-48.9%	-48.9%
6 Month	+4.5%	+4.5%
1 Year	-32.0%	-32.0%

More News

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 18, 2025

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 18, 2025

Via Chartmill

Discover the top movers in Thursday's pre-market session. ↗

December 18, 2025

Via Chartmill

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

December 18, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Participate in Upcoming Investor Conferences

November 03, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

November 03, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

October 13, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

October 09, 2025

From Pyxis Oncology

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 06, 2025

Via Benzinga

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Participate in September Investor and Industry Conferences

August 21, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

April 25, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

April 02, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

March 25, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 18, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

March 03, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

February 26, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

February 04, 2025

From Pyxis Oncology

Via GlobeNewswire

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move ↗

December 20, 2024

Via Benzinga

Frequently Asked Questions

Is Pyxis Oncology, Inc. - Common Stock publicly traded?

Yes, Pyxis Oncology, Inc. - Common Stock is publicly traded.

What exchange does Pyxis Oncology, Inc. - Common Stock trade on?

Pyxis Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pyxis Oncology, Inc. - Common Stock?

The ticker symbol for Pyxis Oncology, Inc. - Common Stock is PYXS on the Nasdaq Stock Market

What is the current price of Pyxis Oncology, Inc. - Common Stock?

The current price of Pyxis Oncology, Inc. - Common Stock is 1.150

When was Pyxis Oncology, Inc. - Common Stock last traded?

The last trade of Pyxis Oncology, Inc. - Common Stock was at 01/02/26 04:00 PM ET

What is the market capitalization of Pyxis Oncology, Inc. - Common Stock?

The market capitalization of Pyxis Oncology, Inc. - Common Stock is 43.98M

How many shares of Pyxis Oncology, Inc. - Common Stock are outstanding?

Pyxis Oncology, Inc. - Common Stock has 44M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.